Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Tremelimumab-actl

(Imjudo®)

Imjudo®

Drug updated on 12/11/2024

Dosage FormInjection (intravenous; 25 mg/1.25 mL [20 mg/mL], 300 mg/15 mL [20 mg/mL])
Drug ClassCytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibodies
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) in combination with durvalumab
  • Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations in combination with durvalumab and platinum-based chemotherapy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of six systematic review(s)/meta-analysis(es). [1-6]
  • Tremelimumab plus durvalumab (Tre + Du) had a comparable overall survival (OS) benefit to atezolizumab plus bevacizumab (Atezo + Beva) (hazard ratio (HR): 1.35, 95% confidence interval (CI): 0.93-1.92), but Atezo + Beva was superior in progression-free survival (PFS) (HR: 0.66, 95% CI: 0.49-0.87).
  • Camrelizumab plus rivoceranib (Camre + Rivo) ranked highest for OS, while lenvatinib plus pembrolizumab (Lenva + Pemb) showed the highest probability of being the best treatment in PFS.
  • Immune checkpoint inhibitor (ICI)-based therapies demonstrated increased effectiveness in the Asia-Pacific group and among hepatitis B virus (HBV)-infected patients, but combined ICI therapies did not show more effectiveness than molecular-targeted drugs in patients without macrovascular invasion or extrahepatic spread.
  • Durvalumab Plus Tremelimumab (DT): Any adverse events (AEs) occurred in 77.8% (95% CI: 67.9-87.6) of patients, Grade ≥ 3 AEs in 29.3% (95% CI: 24.2-34.4), serious AEs in 34.9% (95% CI: 28.1-41.7), and AEs leading to discontinuation in 13.3% (95% CI: 9.3-17.4). Treatment-related deaths were 0.98% (95% CI: 0.5-1.5). Common AEs (>15%): fatigue (30.1%), diarrhea (21.7%), pruritus (17.9%), decreased appetite (17.7%), and nausea (15.6%).
  • Atezolizumab Plus Bevacizumab: Associated with a higher risk of Grade 3 AEs compared to other drugs but provided superior or comparable effectiveness.
  • ICI-based treatments demonstrated increased effectiveness in the Asia-Pacific group and among HBV-infected individuals, while comparable benefit was observed for tremelimumab-durvalumab in subgroups like hepatitis B, nonviral hepatocellular carcinoma (HCC), and alpha-fetoprotein (AFP) ≥ 400 μg/L. Anti-PD-(L)1/vascular endothelial growth factor (VEGF) Ab ranked highest across most subgroups, except in hepatitis B, where atezolizumab-cabozantinib showed superior outcomes for both OS and PFS.